MAPS II: updated guidelines for preneoplastic gastric lesions

  • Pimentel-Nunes P & al.
  • Endoscopy
  • 6 Mar 2019

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • 4 European societies released updated guidelines (MAPS II) for managing patients with precancerous conditions and lesions.

Why this matters

  • Gastric cancer is often fatal when diagnosed, making early detection and management crucial.

Key points

  • High-definition endoscopy with chromoendoscopy (CE) is better than high-definition white-light endoscopy for gastric adenocarcinoma diagnosis and risk stratification of patients with chronic atrophic gastritis or intestinal metaplasia (IM).
  • Virtual CE can target neoplastic lesions and guide biopsies for staging atrophic and metaplastic changes. Two sites (antrum and corpus) should be biopsied and labeled in separate vials.
  • No evidence supports surveillance of mild to moderate atrophy restricted to the antrum.
  • For single-location IM with a family history of gastric cancer, incomplete IM, or persistent Helicobacter pylori gastritis, clinicians may use CE surveillance and guided biopsies at 3 years.
  • Surveil advanced atrophic gastritis using high-quality endoscopy every 3 years.
  • Immediately reassess dysplasia without an endoscopically defined lesion, using high-quality CE.
  • Stage and treat patients with an endoscopically visible lesion with low- or high-grade dysplasia or carcinoma.
  • Eradicate H pylori in nonatrophic chronic gastritis and neoplasia after endoscopic therapy.
  • Identification and surveillance is cost-effective for patients with precancerous gastric conditions in intermediate to high-risk regions.